New combo pill for high blood pressure trial pulled before start
NCT ID NCT02493322
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test whether a new fixed-dose combination of two blood pressure medicines (olmesartan and chlorthalidone) works as well as an existing combination (olmesartan and hydrochlorothiazide) in people with untreated high blood pressure. The trial was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olmesartan medoxomil + chlorthalidone (fixed-dose combination)
- What this could lead to
- If successful, this could offer a new once-daily pill option for controlling high blood pressure.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination would have been safer or more effective than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.